Voisin Consulting Life Sciences publication icon
Publication

Accelerating development, registration and access to medicines for rare diseases in the European Union through adaptive approaches features and perspectives

Post thumbnail Accelerating development, registration and access to medicines for rare diseases in the European Union through adaptive approaches features and perspectives

Accelerating development, registration and access to medicines for rare diseases in the European Union through adaptive approaches: features and perspectives

There is growing recognition that the current research-and-development (R&D) and innovation-regulation ecosystem could be made more efficient to stimulate and support access to innovative therapies for those patients with rare, life-threatening diseases for which there are no adequate licensed therapies.

Emmanuelle Voisin, David Uguen

2014 – Orphanet Journal of Rare Diseases

Voisin Consulting Life Sciences download icon

Download the full publication now

Fill in the form to download the content
Yes, I would like to receive communications regarding VCLS services and events


publication by

Emmanuelle M. Voisin, PhD
Emmanuelle M. Voisin, PhD
Founder and CEO
Dr. Emmanuelle Voisin founded Voisin Consulting Life Sciences (VCLS) in 1997. The firm has become a leading advisor to Biotech,…
View profile
David Uguen thumbnail
David Uguen
Executive Director Drugs and Biologics
David Uguen is responsible for the management of projects involving the design and implementation of regulatory strategies for the development of drugs and biologics. David gained a 18-year experience in European regulatory affairs applied to the development, registration and maintenance of both pharmaceutical and biotechnology medicinal products.